Trial Profile

Phase II Trial of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Primary Immune Deficiencies, Immune Dysregulatory Syndromes, and Inherited Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary)
Indications Graft-versus-host disease
Focus Therapeutic Use

06 Dec 2024 Planned End Date changed from 31 Dec 2026 to 31 Dec 2028.
06 Dec 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2027.
23 Jan 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com